Identification of a Selective YTHDF1 Inhibitor Targeting the m 6 A Recognition Domain for Breast Cancer
Angewandte Chemie International Edition · 06.10.2025 · 64 (41)
DOI: 10.1002/anie.202509316 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 19.08.2025. Verfasst von Yongya Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biotherapy and Cancer Center, Innovation Center of Nursing Research, Children's Medicine Key Laboratory of Sichuan Province, …. Hauptthemen laut MEDLINE: Breast Neoplasms, RNA-Binding Proteins, Adenosine, Antineoplastic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Foundation for Innovative Research Groups of the Natural Science Foundation of Sichuan Province, Youth Fund of the Natural Science Foundation of Sichuan Province.
Abstract (Originalsprache)
As a key N 6 ‐methyladenosine (m 6 A) reader, YTH domain‐containing family protein 1 (YTHDF1) promotes protein synthesis by recognizing m 6 A‐modified mRNA, and its abnormal expression is closely related to breast cancer (BC) progression. To date, the scarce reported YTHDF1 inhibitors suffer from poor selectivity and limited potency, primarily due to the high homology of the YTH domain within the YTHDF family, which poses significant challenges for the discovery of subtype‐selective inhibitors. Here, we report SKLB‐Y13 , the first small‐molecule inhibitor achieving exclusive targeting of the YTHDF1 m 6 A‐binding pocket (IC 50 = 0.76 µM), via structural optimization of a novel 4,5,6,7‐tetrahydrothieno[2,3‐ c ]pyridine scaffold. Uniquely, SKLB‐Y13 interacts with YTHDF1‐specific residues Tyr397 and Trp470, as confirmed by site‐directed mutagenesis, and demonstrates improved selectivity for YTHDF1 over YTH family proteins. Cellular and in vivo studies reveal that SKLB‐Y13 disrupts YTHDF1‐ PRPF6 mRNA interaction in an m 6 A‐dependent manner, thereby impairing the translation of PRPF6 and inhibiting BC proliferation while promoting apoptosis. Chemical proteomics profiling confirms its good target specificity, while pharmacokinetic analysis shows favorable in vivo properties. This study introduces the first selective YTHDF1 inhibitor, serving as a novel chemical probe to elucidate m 6 A‐dependent oncogenesis and a promising starting point for developing precision therapies against YTHDF1‐overexpressing BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Biotherapy and Cancer Center, Innovation Center of Nursing Research, Children's Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, No. 17, Section 3, Renmin Sou…
ORCID-Profile: Liang Ouyang
Förderung
- National Natural Science Foundation of China
- Foundation for Innovative Research Groups of the Natural Science Foundation of Sichuan Province
- Youth Fund of the Natural Science Foundation of Sichuan Province
- Chengdu Municipal Science and Technology Program
- China Postdoctoral Science Foundation
- Sichuan University Postdoctoral Interdisciplinary Innovation Fund
Zitieren
APA
Wu, Y., Feng, G., Shuai, W., Yang, X., Pan, X., Zhu, C., Wang, A., Sun, Q., Wang, G., & Ouyang, L. (2025). Identification of a Selective YTHDF1 Inhibitor Targeting the m 6 A Recognition Domain for Breast Cancer. Angewandte Chemie International Edition, 64(41). https://doi.org/10.1002/anie.202509316
Vancouver
Wu Y, Feng G, Shuai W, Yang X, Pan X, Zhu C, et al. Identification of a Selective YTHDF1 Inhibitor Targeting the m 6 A Recognition Domain for Breast Cancer. Angewandte Chemie International Edition. 2025;64(41). doi:10.1002/anie.202509316
BibTeX
@article{Wu2025,
author = {Wu, Yongya and Feng, Guotai and Shuai, Wen and Yang, Xiao and Pan, Xiaoli and Zhu, Chunyan and Wang, Aoxue and Sun, Qiu and Wang, Guan and Ouyang, Liang},
title = {Identification of a Selective YTHDF1 Inhibitor Targeting the m 6 A Recognition Domain for Breast Cancer},
journal = {Angewandte Chemie International Edition},
year = {2025},
volume = {64},
number = {41},
doi = {10.1002/anie.202509316}
}
EUVIMED